Aerosol BCG treatment of carcinoma metastatic to the lung: A phase I study

Fredric B. Garner, Carol A. Meyer, Deborah S. White, Allan Lipton

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BCG (TICE) was safely administered to 15 patients with metastatic cancer to the lungs in weekly doses of up to 3 × 107 organisms by the aerosol route. The aerosol route of administration is associated in approximately 33% of the doses with a toxicity syndrome of malaise, fever, and chills beginning 4 to 8 hours after treatment and ending within 24–36 hours. This syndrome is experienced by all patients and symptoms gradually subside with continuation of therapy. No hepatic or pulmonary toxicity was documented during the 221 treatment doses.

Original languageEnglish (US)
Pages (from-to)1088-1094
Number of pages7
JournalCancer
Volume35
Issue number4
DOIs
StatePublished - Jan 1 1975

Fingerprint

Mycobacterium bovis
Aerosols
Carcinoma
Lung
Chills
Lung Neoplasms
Fever
Therapeutics
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Garner, Fredric B. ; Meyer, Carol A. ; White, Deborah S. ; Lipton, Allan. / Aerosol BCG treatment of carcinoma metastatic to the lung : A phase I study. In: Cancer. 1975 ; Vol. 35, No. 4. pp. 1088-1094.
@article{27c382e557b84094a9406c59bc84373b,
title = "Aerosol BCG treatment of carcinoma metastatic to the lung: A phase I study",
abstract = "BCG (TICE) was safely administered to 15 patients with metastatic cancer to the lungs in weekly doses of up to 3 × 107 organisms by the aerosol route. The aerosol route of administration is associated in approximately 33{\%} of the doses with a toxicity syndrome of malaise, fever, and chills beginning 4 to 8 hours after treatment and ending within 24–36 hours. This syndrome is experienced by all patients and symptoms gradually subside with continuation of therapy. No hepatic or pulmonary toxicity was documented during the 221 treatment doses.",
author = "Garner, {Fredric B.} and Meyer, {Carol A.} and White, {Deborah S.} and Allan Lipton",
year = "1975",
month = "1",
day = "1",
doi = "10.1002/1097-0142(197504)35:4<1088::AID-CNCR2820350411>3.0.CO;2-2",
language = "English (US)",
volume = "35",
pages = "1088--1094",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

Aerosol BCG treatment of carcinoma metastatic to the lung : A phase I study. / Garner, Fredric B.; Meyer, Carol A.; White, Deborah S.; Lipton, Allan.

In: Cancer, Vol. 35, No. 4, 01.01.1975, p. 1088-1094.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aerosol BCG treatment of carcinoma metastatic to the lung

T2 - A phase I study

AU - Garner, Fredric B.

AU - Meyer, Carol A.

AU - White, Deborah S.

AU - Lipton, Allan

PY - 1975/1/1

Y1 - 1975/1/1

N2 - BCG (TICE) was safely administered to 15 patients with metastatic cancer to the lungs in weekly doses of up to 3 × 107 organisms by the aerosol route. The aerosol route of administration is associated in approximately 33% of the doses with a toxicity syndrome of malaise, fever, and chills beginning 4 to 8 hours after treatment and ending within 24–36 hours. This syndrome is experienced by all patients and symptoms gradually subside with continuation of therapy. No hepatic or pulmonary toxicity was documented during the 221 treatment doses.

AB - BCG (TICE) was safely administered to 15 patients with metastatic cancer to the lungs in weekly doses of up to 3 × 107 organisms by the aerosol route. The aerosol route of administration is associated in approximately 33% of the doses with a toxicity syndrome of malaise, fever, and chills beginning 4 to 8 hours after treatment and ending within 24–36 hours. This syndrome is experienced by all patients and symptoms gradually subside with continuation of therapy. No hepatic or pulmonary toxicity was documented during the 221 treatment doses.

UR - http://www.scopus.com/inward/record.url?scp=0016685290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016685290&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197504)35:4<1088::AID-CNCR2820350411>3.0.CO;2-2

DO - 10.1002/1097-0142(197504)35:4<1088::AID-CNCR2820350411>3.0.CO;2-2

M3 - Article

C2 - 234787

AN - SCOPUS:0016685290

VL - 35

SP - 1088

EP - 1094

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -